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A B S T R A C T
Background: Rheumatoid arthritis (RA) is associated with an increased incidence of atrial ﬁbrillation (AF).
This study evaluated the safety and efﬁcacy of catheter ablation (CA) in the treatment of AF in patients
with RA, which has not been previously reported.
Methods: A total of 15 RA patients with AF who underwent CA were enrolled. For each RA patient, we
selected 4 individuals (control group, 60 patients in total) who presented for AF ablation in the absence of
structural heart or systemic disease and matched the RA patients with same gender, age (2 years), type
of AF, and procedure date.
Results: Patients with RA had a signiﬁcantly higher C-reactive protein level (1.81  2.35 mg/dl vs.
4.14  2.30 mg/dl, p = 0.0320), white blood cell count (5632  1200 mm3 vs. 6361  1567 mm3, p = 0.0482),
and neutrophil count (3308  973 mm3 vs. 3949  1461 mm3, p = 0.0441). At 2-year follow-up, atrial
tachyarrhythmia (ATa) recurrence rate in the RA group (33.3%, 5/15) was similar to that in the control group
(31.7%, 19/60; p = 0.579) after single procedure. In all the ﬁve patients from the RA group who developed
recurrence, ATa relapsed within 90 days following index procedure (median recurrence time 18 days vs.
92 days in control group; p = 0.0373). Multivariate Cox regression analysis showed that hypertension and left
atrial diameter but not RA, C-reactive protein, white blood cell count, and neutrophil count were independent
predictors of ATa recurrence.
Conclusions: Catheter ablation of AF can be safely performed in patients with RA, with a success rate
comparable to that of patients without RA. RA patients tend to develop early ATa recurrence after AF
ablation.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
with an estimated worldwide prevalence of 1–2%. The incidence of
atrial ﬁbrillation (AF) is 40% higher in RA patients than in the
general population, and RA has its own associated morbidity and
mortality [1,2]. Atrial ﬁbrillation can occur at any time during the
course of RA, although it may present as the ﬁrst manifestation of* Corresponding author at: No. 2 Beijing Anzhen Road, Chaoyang District, Beijing
100029, China. Tel.: +86 10 64456412; fax: +86 10 64456078.
E-mail address: chshma@vip.sina.com (C.-S. Ma).
http://dx.doi.org/10.1016/j.jjcc.2014.12.003
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsthe disease [2]. The risk of AF in patients with RA is known to be
increased by several factors including heart failure and ischemic
heart disease [3]. Catheter ablation (CA) has been proven
successful in the treatment of AF in patients with or without
structural heart disease [4]. This approach might be considered as
the ﬁrst-line therapy in patients with AF and systemic disorders as
use of antiarrhythmic drugs (AAD) in this population is either
contraindicated, scarcely effective, or associated with more
adverse effects. For instance, RA is commonly accompanied by
other autoimmune rheumatic diseases such as systemic sclerosis
or vasculitis and pulmonary hypertension where b-blocker use
should be avoided [5]. This study evaluated the safety and efﬁcacy
of CA in the treatment of AF in patients with RA. reserved.
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Study population
Between April 2008 and March 2013, 15 RA patients with AF
underwent their primary CA at our center (RA group, 9 paroxysmal
AF and 6 persistent AF). The diagnosis of RA in these 15 patients
followed the American Rheumatism Association Guidelines [6]. For
each RA patient, we selected four control patients from our
database. These 60 individuals (control group) presented for AF
ablation in the absence of structural heart or systemic disease
including RA and matched the 15 RA patients with same gender,
age (2 years), type of AF, and procedure date.
Laboratory analyses
Full blood samples were collected on the second morning
following hospitalization after overnight fasting. All samples were
immediately cooled on ice and centrifuged twice at 2000  g for
15 min. Plasma was stored at 80 8C. Quantitative determination
of plasma C-reactive protein (CRP) levels was performed by a high
sensitivity CRP assay using a nephelometer (Dade Behring Inc.,
Newark, DE, USA). The inter-assay coefﬁcient of variation was 6.4%.
Plasma white blood cell (WBC) counts and differential leukocyte
counts were measured with a hematology analyzer (Serono-Baker
Diagnostics System 9000, Allentown, PA, USA). The normal range of
WBC counts at our central laboratory was 4.0–12.0  109/L.
Electrophysiology study and AF ablation
All AAD except for amiodarone were stopped for at least ﬁve
half-lives and amiodarone was stopped for at least 2 months before
ablation. Before the procedure, the presence of a left atrial thrombus
was excluded by transesophageal echocardiography. All patients
provided written informed consent. After overnight fasting, the
procedure was performed with patients under conscious sedation.
Our technique for AF ablation has been previously described
[7]. Brieﬂy, a deﬂectable decapolar catheter was positioned in the
coronary sinus (CS). After a successful single transseptal puncture, a
3.5-mm irrigated ablation catheter (NAVISTAR1 THERMOCOOL1,
Biosense-Webster Inc., Diamond Bar, CA, USA) was advanced to the
LA for mapping and subsequent ablation that was guided by a three-
dimensional electroanatomic mapping system (CARTO, Biosense-
Webster Inc.). In patients with paroxysmal AF, complete pulmonary
vein isolation (PVI) was achieved by continuous circular lesions
around ipsilateral pulmonary vein antrum. Cavo-tricuspid isthmus
(CTI) ablation was added in patients with electrocardiogram (ECG)-
documented typical atrial ﬂutter. Ablation strategy in patients with
persistent AF included PVI and linear ablation across the left atrial
(LA) rooﬂine, mitral isthmus (MI) and CTI. If AF was sustained or
converted to an organized atrial tachyarrhythmia, cardioversion
was applied. Achievement of PVI and complete conduction block of
the three linear lesions were used as the procedural end-point in
persistent AF patients. Radiofrequency energy was delivered with a
maximum temperature of 45 8C, a power up to 35 W, and a ﬂow rate
of 17 mL/min. When ablating inside CS, the maximum power was
decreased to 25 W while the ﬂow rate was increased to 30 mL/min.
At each site, the ablation time was restricted to 30–60 s but no more
than 30 s when ablating on the LA posterior wall and inside CS.
Follow-up
All patients were put on previously ineffective AAD which was
discontinued 3 months after the procedure. Follow-up was
scheduled at 1, 3, 6, and 12 months after the procedure when
12-lead ECG and 24 h Holter monitoring were obtained. Inaddition, at any time when a patient experienced symptoms
suggesting arrhythmia, an ECG was recorded. Telephone interview
was conducted monthly by a research associate. Arrhythmia
recurrence was deﬁned as any kind of atrial tachyarrhythmia (AF,
atrial ﬂutter, or atrial tachycardia) of >30 s duration in the absence
of AAD, documented by ECG or Holter monitoring. The duration of
the follow-up was counted from the day of index ablation
procedure. No blanking period was applied [8]. AF recurrence
within 3 months post-ablation was deﬁned as early recurrence;
otherwise, it was deﬁned as late recurrence.
Statistical analysis
Variables are expressed as the mean  SD or number and
percentage, as appropriate. For patient characteristics, continuous
variables were compared with a linear mixed-effects regression model
in which the group variable (the RA or control group) was considered
as a ﬁxed effect and the subject identiﬁcation variable as a random
effect. Categorical variables were compared with a conditional Cox
regression model. Variables that were statistically signiﬁcant in
univariate Cox regression models (p-value <0.1) were included in a
multivariate regression model using an ‘‘enter’’ method to determine
whether they remained signiﬁcant after adjustment for potential
confounders. T test was used to compare total procedural time and
ﬂuoroscopy time between two groups, if their distribution did not
deviate signiﬁcantly from the normal distribution (tested with the
Kolmogorov–Smirnov test). Chi-square test was used to compare the
AF recurrence between two groups. Kaplan–Meier curves were plotted
to assess recurrence-free survival, and the log-rank test was used to
make comparisons between groups. The time to recurrence of AF was
compared with a stratiﬁed Cox proportional hazards regression model,
to estimate the independent predictors of AF recurrence. A p-value of
<0.05 was considered statistically signiﬁcant. Data were analyzed
with SPSS (version 18.0, SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics
The clinical characteristics of patients in the RA group are
summarized in Table 1. History of RA was 17.6  13.8 (range 3–
50) years. Patients 6, 7, 8, 10, 12, 13, and 15 had moderate or severe
deformity in the proximal interphalangeal and metacarpophalangeal
joints of the hands; while joints of shoulders, elbows, knees, and
ankles were also affected in these patients and the lesions were
destructive. In other patients joint deformity was mild. Speciﬁcally,
none of the patients presented with residual joint swelling prior to
the AF ablation procedure. All patients’ X-rays of the spine and
thoracic cage were normal. Patients 14 and 15 were complicated with
Sjo¨gren’s syndrome and mitral valve insufﬁciency on echocardio-
gram. No evidence of coronary vasculitis, pericarditis/myocarditis,
cardiomyopathy, cardiac amyloidosis, or congestive heart failure was
documented in any subject. None of the RA patients showed anemia,
neutropenia, thrombocytopenia, thrombocytosis, eosinophilia, or
dysfunction of neurological, renal, endocrinal, or gastrointestinal
systems. Five patients were taking methylprednisolone and/or
immunosuppressive agents (Table 1) while the other 10 patients
had not received any anti-RA treatment since at least 2 weeks before
AF ablation.
The demographics of patients between the RA group and the
control group were comparable except for the pre-procedural
WBC/neutrophil count and CRP level (Table 2). Patients with RA
had signiﬁcantly higher CRP levels (1.81  2.35 mg/dl vs.
4.14  2.30 mg/dl, p = 0.0320), WBC count (5632  1200 mm3 vs.
6361  1567 mm3, p = 0.0482), and neutrophil count
(3308  973 mm3 vs. 3949 1461 mm3, p = 0.0441).
Table 1
Clinical characteristics of each patient with rheumatoid arthritis.
Patient
no.
Type
of AF
Gender Age RA duration
(year)
Previous
stroke
Comorbidity Anti-RA
treatment
Pre-procedural
CRP (mg/L)
LAD
(mm)
LVEF Free
from ATa
Recurrent
time (day)
1 PeAF F 62 3 N – N 4.90 33 0.58 Y N
2 PeAF F 72 30 N HTN N 3.54 45 0.53 Y N
3 PAF F 65 5 N HTN Y 5.50 36 0.68 Y N
4 PAF M 77 50 N HTN N 2.80 38 0.65 Y N
5 PAF F 59 8 N – Y 3.26 33 0.57 N 1
6 PeAF F 71 20 Y HTN N 4.96 32 0.63 Y N
7 PAF F 76 10 N HTN N 5.20 38 0.68 N 81
8 PAF F 55 5 N – Y 4.23 32 0.65 Y N
9 PAF F 76 10 Y HTN N 3.36 35.5 0.70 Y N
10 PeAF F 60 8 N HTN N 4.04 46 0.57 Y N
11 PAF M 67 30 N – N 2.79 41 0.60 N 14
12 PAF M 62 20 N – Y 3.20 34 0.65 Y N
13 PAF F 59 30 N HTN N 4.37 37 0.71 Y N
14 PeAF F 72 30 Y DM Y 3.98 45 0.62 N 18
15 PeAF F 52 5 N – N 6.54 57 0.55 N 45
AF, atrial ﬁbrillation; CRP, C-reactive protein; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; PAF, paroxysmal atrial ﬁbrillation; PeAF, persistent atrial
ﬁbrillation; F, female; M, male; N, no; Y, yes; HTN, hypertension; DM, diabetes mellitus; RA, rheumatoid arthritis; ATa, atrial tachyarrhythmia.
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Procedural endpoints were achieved in all patients. There was
no difference in terms of total procedural time (161  69 min
vs.147  66 min, p = 0.46) and ﬂuoroscopy time (27  16 min vs.
32  30 min, p = 0.60) between the RA group and the control group.
None of the patients in either group experienced a major complica-
tion except one in the RA group (Patient 12) who developed groin
hematoma that resolved with manual and bandage compression. In
the RA group, ﬁve patients (33.3%; Patients 5, 7, 11, 14, and 15)
developed atrial tachyarrhythmia (ATa) recurrence. Among them,
three patients (Patients 5, 7, and 11) with paroxysmal AF prior to the
index procedure received a repeat ablation after recurrence. During
the redo procedure, conduction gaps between PVs and LA wereTable 2
Comparison of patients’ demographics between the RA group and the control group.
Control group
(n = 60)
RA group
(n = 15)
p-Value
Male/female, n 12/48 3/12 –
Age (years) 63.57  9.19 63.67  8.02 –
Paroxysmal, n (%) 36 (60.00) 9 (60.00) –
Persistent, n (%) 24 (40.00) 6 (40.00) –
AF duration (years) 5.03  5.22 5.67  5.19 0.6717
Hypertension, n (%) 37 (61.67) 8 (53.33) 0.5623
Diabetes mellitus, n (%) 5 (8.33) 1 (6.67) 0.8020
Stroke, n (%) 15 (25) 3 (20) 0.8020
LVEF (%) 63.06  9.25 63.13  6.79 0.9775
LAD (mm) 39.29  7.16 38.83  6.92 0.8236
Statin 16 (26.67) 5 (33.33) 0.6180
Methylprednisolone 0 (0%) 4 (26.67) 0.0011
Immunosuppressive
agents
0 (0%) 2 (13.33) 0.0378
CRP 1.81  2.35 4.14  2.30 0.0320
Body temperature (8C) 36.3  0.2 36.3  0.1 0.2110
White blood cell count
(#/mm3)
5632  1200 6361  1567 0.0482
Neutrophils (#/mm3) 3308  973 3949  1461 0.0441
Lymphocytes (#/mm3) 1867  525 1963  557 0.5201
Monocytes (#/mm3) 309  102 337  147 0.3870
Neutrophil/lymphocyte
ratio
1.94  0.94 2.16  1.23 0.4290
Hemoglobin (g/dl) 13.1  1.7 12.6  1.8 0.3200
Platelet count (103) 198  44 196  59 0.8880
RA, rheumatoid arthritis; AF, atrial ﬁbrillation; LVEF, left ventricular ejection
fraction; LAD, left atrial diameter; CRP, C-reactive protein.identiﬁed in all these patients and PVI was re-achieved during the
second procedure. Patients 14 and 15 with persistent AF prior to
index procedure had ATa recurrence 18 and 45 days after the initial
ablation. Both patients developed severe mitral regurgitation during
follow-up and were treated with mitral valvuloplasty plus surgical
ablation 3 years later. The other 10 patients in the RA group remained
in sinus rhythm at 2-year follow-up. In the control group, ATa
relapsed in 19 patients (31.7%; p = 0.579 vs. RA group). Apparently, AF
patients with RA were prone to develop early recurrence (median
recurrent time 18 days) compared to those without RA (median
recurrent time 92 days in the control group, p = 0.0373). Speciﬁcally,
in those patients (5 in the RA group and 9 in the control group) who
had early ATa recurrence following the index ablation procedure, the
recurrent tachycardia sustained beyond 90 days until they were
retreated or the end of follow-up. The Kaplan–Meier curves showed
that ATa-free survival between the two groups was borderline
signiﬁcant (log rank p = 0.062) within the ﬁrst 90 days (Fig. 1A) with
AAD but not (log rank p = 0.807) when the follow-up was extended to
2 years (Fig. 1B) after a single procedure.
Predictor of AF recurrence after a single procedure
Based on prior knowledge or expected clinical relevance
[9,10], the following potential confounders were entered into a
Cox regression model which was established in all study
subjects: age, gender, AF type, AF duration, left atrial diameter
(LAD), left ventricular ejection fraction (LVEF), hypertension, RA,
WBC count, neutrophil count, lymphocyte count, neutrophil/
lymphocyte ratio (NLR), monocyte count, and CRP level.
Univariate analysis indicated that hypertension, LAD, WBC count,
and neutrophil count were signiﬁcantly associated with ATa
recurrence (Table 3). Speciﬁcally, pre-procedural CRP level and
the presence of RA were not demonstrated as risk factors of
arrhythmia recurrence after AF ablation. Multivariate Cox
regression analysis showed that hypertension [hazard ratio
(HR) 0.233, 95% conﬁdence interval (CI) 0.072–0.755, p = 0.015]
and LAD (HR 1.113, 95% CI 1.022–1.213, p = 0.014) were
independent predictors of ATa recurrence following CA. Univari-
ate analysis indicated that RA (HR 0.371, 95% CI 0.124–1.109,
p = 0.076), neutrophil count (HR 1.487, 95% CI 0.939–2.354,
p = 0.091), and NLR (HR 2.435, 95% CI 1.187–4.995, p = 0.015)
were associated with early ATa recurrence (p < 0.1); however,
multivariate Cox regression failed to identify any independent
predictor of early ATa recurrence.
Fig. 1. Kaplan–Meier analysis of ATa-free survival in the RA and the control group at
90-day (A) and 2-year (B) follow-up. ATa, atrial tachyarrhythmia; RA, rheumatoid
arthritis.
Table 3
Cox regression analysis for predictors of atrial tachyarrhythmia recurrence.
Variables HR 95% CI p-Value
Age 1.025 0.914–1.149 0.6770
Gender 1.245 0.354–4.376 0.7327
AF type 1.040 0.172–6.298 0.9660
AF duration 1.037 0.967–1.112 0.3074
LAD 1.045 0.999–1.094 0.0160
LVEF 0.906 0.770–1.066 0.2340
Hypertension 0.416 0.185–0.938 0.0340
RA 1.065 0.339–3.341 0.9143
WBC count 1.370 0.857–2.191 0.0880
Neutrophil count 1.487 0.939–2.354 0.0910
Lymphocyte count 0.212 0.020–2.266 0.1990
NLR 1.209 0.823–3.874 0.1620
Monocyte count 1.239 0.314–2.827 0.1180
CRP 1.044 0.921–1.183 0.4996
HR, hazard ratio; CI, conﬁdence interval; AF, atrial ﬁbrillation; LAD, left atrial
diameter; LVEF, left ventricular ejection fraction; RA, rheumatoid arthritis;
WBC, white blood cell; CRP, C-reactive protein; NLR, neutrophil/lymphocyte
ratio.
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The major ﬁndings of this study were (1) CA of AF can be safely
performed in patients with RA and has a success rate comparable
to that of patients without RA, and (2) RA patients tend to develop
early ATa recurrence after AF ablation.
Rheumatoid arthritis is the most common inﬂammatory joint
disease, affecting 1–2% of the population worldwide with more
than two thirds of patients being female. It has been reported that
over 25% of the women with AF have an underlying rheumatologic
condition [11]. However, the relation between these two diseases
remains controversial. Recently, published data from a Danish
cohort showed a 40% increase of the risk of AF in patients with RA
compared to the general population [1]. Although the pathophysi-
ology of AF in the presence of RA is complex and poorlyunderstood, several lines of evidence support the fact that AF is
a common comorbidity in RA [1]. However, Kim et al. failed to
demonstrate such an association in their study [12]. The safety and
effectiveness of CA of AF in patients with RA have not been
reported. Therefore, we performed a retrospective study to
investigate the effect of CA on the outcome of patients with RA
who underwent AF ablation. We found that CA could be safely
performed in patients with RA and had a success rate comparable
to that of patients without RA.
Systemic inﬂammation plays an important role in the initiation,
maintenance, and recurrence of AF [13]. Elevated level of CRP has
been suggested to be related to the initiation or maintenance of AF.
The WBC count and subtypes, such as neutrophil, lymphocyte,
monocyte, and NLR, are readily available biomarkers of systemic
inﬂammation and associated with AF. After CA, an increased level
of inﬂammatory biomarkers was correlated with the amount of
radiofrequency delivery and was associated with early recurrence
[14]. In the present study, patients with RA had a signiﬁcantly
higher CRP level, WBC count and neutrophil count, but Cox
regression analysis showed that none of them was an independent
predictor of ATa recurrence. Actually, a recent cohort study found
an independent association between CRP and AF risk in men, but
not in women [15]. Rheumatoid arthritis is more prevalent in
women and 80% of the patients in the RA group were females.
Interestingly, all recurrent patients in the RA group experienced
ATa relapse within 90 days following CA. In all the RA patients
involved in the present study, it appeared that the disease was
clinically inactive either spontaneously or under drug control. They
presented with a relative lower level of inﬂammatory biomarkers
compared to a previous report [16]. So the pre-procedural status of
systemic inﬂammation might no longer contribute to the outcome
(early or late ATa recurrence) after AF ablation. However, we
speculated that these patients may have robust local and systemic
inﬂammatory responses to CA, which led to a high incidence of
early recurrence even with AAD in the RA group.
Given the pathogenic role of inﬂammation in AF recurrence and
maintenance after ablation, it has been postulated that therapies
aggressively targeting peri-procedural inﬂammation might reduce
the risk of development of AF. A recent meta-analysis demonstrat-
ed that intravenous corticosteroid therapy before and/or after
cardiopulmonary bypass and cardiac surgery was associated with a
signiﬁcant reduction in incidence of post-operative AF [17]. The
model of post-operative AF resembles that of AF recurrence after
CA, because in both of these clinical scenarios, a strong
inﬂammatory reaction comes into play [8]. Previously, Koyama
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prednisolone resulted in a signiﬁcant reduction in peri-procedural
inﬂammatory biomarkers and a reduced rate of immediate AF
recurrence after CA. However, in the present study, ﬁve RA patients
were under steroids and/or immunosuppressive agents therapy
but two of them developed early recurrence. Although no
statistical analysis was applied due to the small sample size, it
appeared that the regular anti-inﬂammatory treatment is not
preventing early ATa relapse in the RA patients as they may have
pronounced inﬂammatory reaction immediately after ablation. In
fact, a few studies have indicated that use of non-aspirin non-
steroidal antiinﬂammatory drugs or glucocorticoids was associat-
ed with an increased risk of AF or ﬂutter [18,19]. Whether the
current anti-RA therapy will produce favorable or unfavorable
effects on the outcome of AF ablation in RA patients remains
unclear.
Although recurrence in blanking period usually is not consid-
ered as treatment failure, their prognostic value for later AF
recurrence is high [20]. The initial extensive myocardial damage
caused by radiofrequency CA is followed by a local and systemic
inﬂammatory response [14]. So, numerous studies have found that
inﬂammatory responses appeared shortly after CA and that those
responses were closely associated with early AF recurrence,
usually within the ﬁrst 3-month ‘‘blanking period’’ [21]. Actually,
in Deftereos’s study [8] the authors did not apply a blanking period
when they investigated the effect of colchicine on preventing early
AF recurrence after CA. Similarly, in our study patients with RA
have a strong background of systemic inﬂammation. So we did not
apply a blanking period when evaluating procedural outcome and
found that RA patients were more prone to develop early ATa
recurrence compared to the control subjects. Of note, in both
groups none of the early recurrent ATa (occurring within 90 days
after ablation) spontaneously terminated during follow-up.
The study also revealed that LAD is another independent risk
factor for recurrence, consistent with previous studies [22]. In-
creased LA size might be a consequence, at least in part, of chronic
inﬂammatory state and atrial myocardial ﬁbrosis under condition
of RA.
Our study had some limitations. This was an observational
study of a cohort of patients from a single center. The number of
patients with RA enrolled in our study was small. Finally, we did
not have data of inﬂammatory biomarkers after ablation or during
follow-up, making the comparison to the pre-procedural data
impossible.
In conclusion, CA of AF can be safely performed in patients with
RA, with an overall success rate comparable to that in patients
without RA. Patients with RA tend to develop early ATa recurrence
within 3 months following an ablation procedure, which might be
attributed to an immediate, robust inﬂammatory reaction induced
by CA in this speciﬁc population.
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